All In Biotech

Drug Trial Radar · NCT05426486

A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients

A Randomized, Open Label, Multi-center Phase II-III Neoadjuvant Study Comparing the Efficacy and Safety of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) in Patients With HER2-positive Breast Cancer

Last checked: Nov 19, 2026Latest source record: Oct 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 136 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

136

Planned (sponsor's estimate)

Start

May 23, 2022

Primary completion

Dec 30, 2025

Study completion Dec 30, 2028

Sponsor

Lead sponsor
Caigang LiuAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 22, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, open label Phase II-III neoadjuvant study comparing the efficacy and safety of ARX788 combined with pyrotinib maleate versus TCBHP (trastuzumab plus pertuzumab with docetaxel and carboplatin) in patients with HER2-positive breast cancer.

Conditions

  • HER2-positive Breast Cancer

Interventions

  • ARX788Drug

    HER2 antibody-drug conjugate

  • Pyrotinib maleateDrug

    EGFR/HER2 dual inhibitor

  • TrastuzumabDrug

    anti-Her2 monoclonal antibody

  • PertuzumabDrug

    anti-HER2 monoclonal antibody

  • DocetaxelDrug

    Cytotoxic chemotherapy

  • CarboplatinDrug

    Cytotoxic chemotherapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Total pathological complete response rate (tpCR) rateTime frame: 3 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shengjing Hospital affiliated to China Medical University

    Shenyang, Liaoning, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.